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ABSTRACT
OBJECTIVE
To investigate whether the genetic burden of type 2 
diabetes modifies the association between the quality 
of dietary fat and the incidence of type 2 diabetes.
DESIGN
Individual participant data meta-analysis.
DATA SOURCES
Eligible prospective cohort studies were systematically 
sourced from studies published between January 
1970 and February 2017 through electronic searches 
in major medical databases (Medline, Embase, and 
Scopus) and discussion with investigators.
REVIEW METHODS
Data from cohort studies or multicohort consortia with 
available genome-wide genetic data and information 
about the quality of dietary fat and the incidence of 
type 2 diabetes in participants of European descent 
was sought. Prospective cohorts that had accrued five 
or more years of follow-up were included. The type 2 
diabetes genetic risk profile was characterized by a 
68-variant polygenic risk score weighted by published 
effect sizes. Diet was recorded by using validated 
cohort-specific dietary assessment tools. Outcome 
measures were summary adjusted hazard ratios of 
incident type 2 diabetes for polygenic risk score, 
isocaloric replacement of carbohydrate (refined starch 
and sugars) with types of fat, and the interaction of 
types of fat with polygenic risk score.
RESULTS
Of 102 305 participants from 15 prospective 
cohort studies, 20 015 type 2 diabetes cases were 
documented after a median follow-up of 12 years 
(interquartile range 9.4-14.2). The hazard ratio of 
type 2 diabetes per increment of 10 risk alleles in 
the polygenic risk score was 1.64 (95% confidence 
interval 1.54 to 1.75, I2=7.1%, τ2=0.003). The 
increase of polyunsaturated fat and total omega 6 
polyunsaturated fat intake in place of carbohydrate 
was associated with a lower risk of type 2 diabetes, 
with hazard ratios of 0.90 (0.82 to 0.98, I2=18.0%, 
τ2=0.006; per 5% of energy) and 0.99 (0.97 to 
1.00, I2=58.8%, τ2=0.001; per increment of 1 g/d), 
respectively. Increasing monounsaturated fat in place 
of carbohydrate was associated with a higher risk of 
type 2 diabetes (hazard ratio 1.10, 95% confidence 
interval 1.01 to 1.19, I2=25.9%, τ2=0.006; per 5% of 
energy). Evidence of small study effects was detected 
for the overall association of polyunsaturated fat with 
the risk of type 2 diabetes, but not for the omega 
6 polyunsaturated fat and monounsaturated fat 
associations. Significant interactions between dietary 
fat and polygenic risk score on the risk of type 2 
diabetes (P>0.05 for interaction) were not observed.
CONCLUSIONS
These data indicate that genetic burden and the 
quality of dietary fat are each associated with the 
incidence of type 2 diabetes. The findings do not 
support tailoring recommendations on the quality of 
dietary fat to individual type 2 diabetes genetic risk 
profiles for the primary prevention of type 2 diabetes, 
and suggest that dietary fat is associated with the 
risk of type 2 diabetes across the spectrum of type 2 
diabetes genetic risk.
Introduction
Diabetes is regarded as one of the most serious public 
health challenges of the 21st century, affecting the 
health of an estimated 8.8% people in 2017, which is 
projected to increase to 9.9% by 2045.1 The individual 
risk of type 2 diabetes reflects the interplay between 
lifestyle and dietary factors acting on a backdrop of 
genetic predisposition.2
Currently, 243 genetic loci are associated with the 
risk of type 2 diabetes in successive waves of large-
scale genetic association studies.3-6 These risk alleles, 
when aggregated into a polygenic risk score, can 
provide a continuous measure of the genetic risk and 
are predictive of incident type 2 diabetes.3 7 However, 
the extent to which the risk of the disease conferred 
by the presence of type 2 diabetes risk-increasing 
alleles can be modified by dietary factors is unclear.8 9 
A previous prospective study suggested that genetic 
predisposition could interact with a Western dietary 
pattern to determine the risk of type 2 diabetes in 
men,8 but no interaction was detected between a type 
2 diabetes polygenic risk score and a Mediterranean 
diet score on the development of type 2 diabetes in the 
InterAct study.9 Integrating genetic and environmental 
information represents one of the greatest challenges 
facing the implementation of precision medicine in 
metabolic diseases.2 10 11
Recommendations aimed at improving dietary 
quality are an essential part of preventing and 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Type 2 diabetes is a complex disease driven by genetic and lifestyle factors
Dietary recommendations aiming to improve dietary quality are a critical part of 
type 2 diabetes prevention and treatment
WHAT THIS STUDY ADDS
Genetic risk and quality of dietary fat are each associated with the incidence of 
type 2 diabetes
Dietary or lifestyle interventions for type 2 diabetes should be deployed across 
all gradients of genetic risk in the population, as genetic burden does not seem 
to impede their effectiveness
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treating type 2 diabetes, as reflected in current 
dietary guidelines. These guidelines recommend 
dietary patterns rich in unsaturated fatty acids, 
polyunsaturated fats in particular, and limited in 
saturated fat and sugars to reduce the risk of type 2 
diabetes.12 13 However, major gaps in the evidence for 
the relation between the quality of dietary fat and the 
risk of type 2 diabetes exist, including uncertainty 
on the benefits of increasing monounsaturated fat in 
place of carbohydrate and uncertainty on the effects 
of saturated fat.12-16 To promote appropriate dietary 
patterns, it is essential to know whether individual 
nutrients and food groups affect chronic diseases such 
as type 2 diabetes.17
In this study, we undertook an individual participant 
data meta-analysis to investigate the association of 
the quality of dietary fat with the incidence of type 
2 diabetes and to evaluate whether the presence of 
known type 2 diabetes risk-increasing alleles modify 
the association between subtypes of fat and the risk of 
type 2 diabetes.
Methods
Study design, search strategy, and selection criteria
We elaborated an analysis plan, including harmonized 
definitions of exposures, outcomes, and covariates 
for combining individual participant data from 
prospective cohort studies or multicohort consortia. 
Our main research question was to investigate whether 
the presence of known type 2 diabetes risk-increasing 
alleles modifies the association between the quality 
of dietary fat and the risk of type 2 diabetes. The 
prespecified analysis plan is provided in appendix 
1. This article follows Preferred Reporting Items for 
Systematic reviews and Meta-Analysis of Individual 
Participant Data (PRISMA-IPD) reporting guidelines 
(appendix 2).18
We sought data from large prospective cohort studies 
or large multicohort consortia through a systematic 
literature search and discussion with investigators 
(appendix 3). Two independent researchers conducted 
the electronic searches in Medline, Embase, and 
Scopus from studies published between January 1970 
and February 2017 with the terms “diet” or “dietary 
fat” or “fat quality” or “fat intake,” or “genetics” or 
“genotype” or “gene,” or “diabetes,” or “cohort” or 
“prospective,” and a combination of the words “risk,” 
“relative,” “hazard,” or “ratio.” There were no language 
restrictions. Prospective cohort studies were eligible if 
they had genome-wide genetic data and information 
about the quality of dietary fat and the incidence of 
type 2 diabetes; included more than 500 patients of 
European ancestry, not selected on the basis of having 
any previous chronic disease; recruited adults (aged 
≥20 and ≤80 at baseline); and had accrued five years or 
more of median follow-up that allowed time dependent 
analyses. On identification of eligible cohorts, lead 
investigators from each contributing cohort were asked 
to participate in a standardized individual participant 
data meta-analysis of the quality of dietary fat, genetic 
risk, and the incidence of type 2 diabetes by March 
2017. Before data analysis, candidate cohorts were 
requested to provide information on type 2 diabetes 
risk-increasing variants and descriptive statistics of 
total and subtypes of dietary fat. Within participating 
cohorts, we excluded patients of non-European 
ancestry, patients with prevalent diabetes, patients 
who reported implausible baseline energy intake 
(<500 or >4500 kcal/d; 1 kcal = 4.18 kJ = 0.00418 
MJ), patients who had missing genetic or quality of 
dietary fat data, or patients aged under 20 and over 80 
at baseline (appendix 1). The rationale for excluding 
patients who reported implausible energy intake was 
based on potential confounding or bias associated 
with extreme energy intake. We also excluded patients 
who had missing genetic information as we are unable 
to quantify genetic risk in the absence of genetic data. 
To limit bias owing to effects of pre-existing disease on 
dietary intake (such as, reverse causality), the primary 
analysis was restricted to patients without specific 
known chronic diseases at baseline (such as, cancer 
or cardiovascular disease). Institutional Review Board 
or oversight committees, or both, approved the study 
in each participating cohort and all patients provided 
written informed consent.
Study outcome
The primary outcome for this analysis was incidence 
of type 2 diabetes. The details of the methods used 
for defining endpoint adjudication in each pros-
pective cohort are described in appendix 4. In brief, 
ascertainment of type 2 diabetes was defined by fasting 
or non-fasting glucose determinations, treatment with 
either insulin or a hypoglycemic agent at the follow-
up examinations, or by reviewing multiple sources of 
evidence, including linkage to primary care registers 
and secondary care registers, hospital admissions, and 
mortality data.
Type 2 diabetes polygenic risk score
A total of 88 of the known 89 genome-wide associated 
type 2 diabetes risk-increasing variants reported at 
the time of the analysis were selected for this analysis 
(DUSP9 was excluded owing to its location on the 
X chromosome).3 4 Sixty eight out of the 88 type 2 
diabetes risk-increasing variants were available in all 
participating cohorts either through direct genotyping 
or by imputation with sufficient imputation quality. 
Details regarding the variants included in the polygenic 
risk score, cohort-specific genotyping platform, 
imputation panels, and quality metrics are summarized 
in supplementary tables 1 and 2. Consistent with 
previous studies,7 19 20 we used a weighted method to 
calculate the polygenic risk score on the basis of the 
68 type 2 diabetes variants. Each variant was coded 
with the expected number of type 2 diabetes risk-
increasing alleles and weighted by its relative effect 
size (β coefficient) on type 2 diabetes. β coefficients 
were obtained from a previously published genome-
wide association meta-analysis in 34 840 cases and 
114 981 controls.3 Using these external weights, we 
calculated the polygenic risk score (PRS) for each 
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individual in each cohort by using the equation: PRS = 
(β1 × SNP1 + β2 × SNP2 + … + β68 × SNP68) × (68/sum of 
the β coefficients). The polygenic risk score ranges from 
0 to 136, with each unit corresponding to one average 
risk allele and higher scores indicating a higher genetic 
predisposition to type 2 diabetes.
Assessment of dietary fat quality
We assessed total and subtypes of fat by using validated 
cohort-specific semiquantitative food-frequency que 
stionnaires or diet history (supplementary table 
3). We expressed main dietary variables as percentages 
of energy intake from total and subtypes of fat, 
including polyunsaturated fat (omega 3 and omega 
6 polyunsaturated fat), monounsaturated fat (com 
prising oleic acid, palmitoleic acid, gondoic acid, 
erucic acid, and nervonic acid), and saturated fat 
(including butyric acid, caproic acid, caprylic acid, 
capric acid, lauric acid, myristic acid, palmitic acid, 
and stearic acid). Total omega 3 polyunsaturated fat 
(including dietary α-linoleic acid, eicosapentaenoic 
acid, and docosahexaenoic acid and excluding 
supplementation, n=13 cohorts), total omega 6 
polyunsaturated fat (including linoleic acid and 
arachidonic acid and excluding supplementation, 
n=13 cohorts), and total trans fat (n=11 cohorts) were 
expressed as g/d. Because cumulative averages of 
dietary components yield more precise dietary intake 
estimates than baseline intakes alone,21 cohorts 
with repeated measurements of diet calculated the 
cumulative averages of dietary variables.
Assessment of covariates
Demographic, lifestyle, and clinical characteristics 
were assessed at baseline and during follow-up 
assessments by self report questionnaires or through 
clinical examination. Covariate definitions were 
harmonized across studies and are detailed in 
supplementary table 4. In brief, this information 
included: age (years, continuous), sex (men or women), 
body mass index (BMI, kg/m2, continuous), smoking 
(never, former, or current; if former was not reported 
then current v non-current smoker), physical activity 
(categories of metabolic equivalents, physical activity 
scores, or leisure-time physical activity, as defined 
by individual studies), family history of diabetes (yes 
or no), dyslipidemia (yes or no, defined based on 
treatment with lipid-lowering drugs or diagnosis of 
dyslipidemia), hypertension (yes or no, defined based 
on treatment with antihypertensive drugs or diagnosis 
of hypertension), and dietary factors including total 
energy intake (kcal/d, continuous), protein intake 
(% of energy intake, continuous), dietary fiber (g/d, 
continuous), magnesium intake (g/d, continuous), and 
alcohol intake (g/d, continuous).
Quality assessment of included cohort studies and 
integrity of individual participant data
We assessed the quality of the included cohort studies 
or large multicohort consortia and integrity of the 
individual participant data according to a prespecified 
protocol (appendix 1). Two independent researchers 
assessed the quality of participating cohorts by using 
the Newcastle-Ottawa Scale.22 We considered a study 
to have a low risk of bias if it scored as a such (good 
quality or fair quality) in all the following domains: 
population selection, comparability, and outcome. 
Individual participant data were obtained between 
August and September 2017. Individual participant 
data integrity and data quality control procedures 
comprised range and consistency checks on all 
individual participant data outputs to identify invalid, 
out of range, or disparate items. Errors, missing 
information, or inconsistencies were queried and 
rectified as necessary with input from each analyst 
between September and December 2017.
Data synthesis
We undertook a two stage individual participant data 
meta-analysis to obtain adjusted summary estimates 
of incident type 2 diabetes for polygenic risk score, 
isocaloric replacement of carbohydrate (referred to 
refined starch and sugars) with total or subtypes of 
fat, and the interaction of total or subtypes of fat with 
polygenic risk score.23
In each cohort (first stage of the two stage meta-
analysis), we used Cox proportional hazards models 
to estimate the risk of type 2 diabetes comparing 
type 2 diabetes cases to all other patients without 
diabetes at the end of follow-up after exploring that the 
proportional hazards assumption was not violated. In 
studies with a case cohort design, all Cox proportional 
hazards models were Prentice weighted.24 We modeled 
polygenic risk score, total or subtypes of fat intake, 
and the interaction terms as continuous variables. 
We used polynomials to investigate the presence of a 
non-linear association, and found little evidence of 
a non-linear association when removing outliers in 
total or subtypes of fat intake variables. Therefore, 
we winsorized total or subtypes of fat intake variables 
(±4 SD from the mean). We adjusted the models to 
investigate the association between polygenic risk 
score and the risk of type 2 diabetes for age, sex, BMI, 
smoking, physical activity, parental history of type 2 
diabetes, history of dyslipidemia and hypertension, 
and dietary factors. Additional cohort-specific 
adjustments, including multicenter recruitment site 
or family relatedness, were included as appropriate. 
We used nutrient replacement models to investigate 
the hazard ratios of type 2 diabetes by substituting 
a percentage of energy from total or subtypes of fat 
for equivalent energy from carbohydrate (referred to 
refined starch and sugars because dietary fiber was 
included in the models). These models were further 
adjusted for subtypes of fat specific to each statistical 
model (supplementary table 4). As dietary sources of 
monounsaturated fat might also contain high amounts 
of saturated fat,25 isocaloric replacement models for 
monounsaturated fat accounted for dietary saturated 
fat and total energy to allow for the interpretation of 
the hypothetical replacement of monounsaturated 
fat with carbohydrate, independent of other fatty 
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acids, as described in earlier studies.26-30 Isocaloric 
substitution of fat from carbohydrate represents a 
realistic approach considering that total energy intake 
is primarily balanced between the amount of fat and 
carbohydrate and that calories from saturated fat 
tend to mainly replace low quality carbohydrate.27 31 
In post hoc analyses, we further estimated the effects 
of increasing polyunsaturated fat intake in place of 
saturated fat.
To test the interaction between dietary fat subtypes 
and genetic risk on the risk of type 2 diabetes we used 
Cox proportional hazards models incorporating an 
interaction term between dietary fat variables and 
the polygenic risk score. Given the strong collinearity 
between the interaction term and both dietary fats 
variables and polygenic risk score, we centered these 
variables by using the combined mean value of all 
cohorts as recommended elsewhere.32 We conducted 
further analyses, not prespecified in the analysis plan, 
to investigate whether total or subtypes of fat mediate 
the association between genetic risk and the incidence 
of type 2 diabetes in additional models with and 
without adjustment for total and subtypes of fat. In 
each participating cohort, confounders with more than 
5% of observations missing were handled by multiple 
imputation using chained equations.33 34 If less than 
5% of values were missing, participants with the 
missing information were excluded from the analysis 
(appendix 1, supplementary table 5).
In the second stage of the individual participant data 
meta-analysis, summary statistics provided by each 
cohort were combined by inverse-variance weighted 
random effects meta-analyses (DerSimonian and Laird 
procedure).35 We used between study variance (τ2) to 
assess heterogeneity.36 We conducted additional meta-
analyses iteratively excluding one cohort at a time to 
estimate robustness of the meta-analytic estimates. 
Small study effects owing to potential publication 
bias, poor methodological quality in smaller studies, 
artefactual associations, true heterogeneity, or chance 
were evaluated by using contour-enhanced funnel 
plots alongside visual examination and statistical 
tests for asymmetry (Debray’s test).37 In addition, 
we assessed the possibility of ascertainment bias by 
plotting adjusted estimates from each participating 
cohort study against the percentage of individuals with 
genetic information in each study. We further restricted 
all our analyses to cohorts classified as a low risk of 
bias and cohorts with repeated measurements of diet. 
Finally, we conducted additional analyses by using the 
joint meta-analysis method.38 In brief, the joint meta-
analysis is a multivariate meta-analysis approach that 
simultaneously estimates the main genetic effects and 
interaction term contribution on the risk of type 2 
diabetes.
We considered two sided α level of 0.05 for all 
analyses. Statistical analyses were carried out using 
SAS software, version 9.3 or R software, versions 3.1.0 
and 3.2.0. Meta-analyses and meta regressions were 
conducted using the metafor package implemented in 
R, version 3.2.0 and METAL.39
Patient and public involvement
No patients were directly involved in designing the 
research question or in conducting the research. 
No patients were asked for advice on interpretation 
or writing up the results. There are no plans to 
involve patients or relevant patient community in 
dissemination at this moment.
Results
We identified 19 eligible prospective cohort studies or 
multicohort consortia, of which 15 provided individual 
participant data (appendix 3). A flow diagram of 
Table 1 | Prospective cohort studies that contributed to the meta-analysis of individual participant data on the quality of 
dietary fat and genetic risk of type 2 diabetes
Participating cohorts Abbreviation Country Baseline
Sample 
size
No (%) of type 2 
diabetes incident 
cases
Years of 
follow-up 
Atherosclerosis Risk in  
Communities Study ARIC USA 1987-1989 6690 442 (6.6) 6
Bogalusa Heart Study BHS USA 1998-2001 790 46 (6.6) 5
Cardiovascular Health Study CHS USA 1989-1990 2813 258 (9.2) 20
Diet, Cancer and Health* DCH Denmark 1993-1997 8788 3987 (40.1) 12.5
European Prospective Investigation 
of Cancer-InterAct* EPIC-InterAct
Europe  
(10 countries) 1991-1997 20 856 9257 (44.4) 9.6
Framingham Heart Study FHS USA 1991-1996 6710 289 (4.3) 12
FINRISK Study FINRISK Finland 2007 3822 172 (4.5) 7.6
Health 2000 Health 2000 Finland 2000 1946 138 (7.1) 12.4
Health Professionals’  
Follow-up Study HPFS USA 1986 5587 939 (16.8) 22
Inter99 study Inter99 Denmark 1999 5607 279 (5.5) 11
Malmö Diet and Cancer study MDC-CC USA 1991-1994 3745 440 (11.9) 16
Multi-Ethnic Study of  
Atherosclerosis MESA USA 2000-2002 1535 136 (8.9) 9.1
Nurses’ Health Study NHS USA 1984 8832 1453 (17.1) 28
Rotterdam Study I RS-I The Netherlands 1989 2509 324 (12.9) 10.2
Women’s Genome Health Study WGHS USA 1991 22 120 1855 (8.4) 12
Total 102 350 20 015 (19.6) 12
*Prospective nested case control.
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the study selection and individual participant data 
obtained is detailed in supplementary figure 1. 
Descriptions and baseline characteristics of included 
prospective cohort studies or multicohort consortia 
are detailed in table 1 and appendix 4. Overall, 
participating prospective cohort studies had a low risk 
of bias in population selection, comparability, and 
outcome domains (supplementary table 6). We did not 
encounter issues that we were unable to resolve with 
the individual participant data contributor during the 
individual participant data integrity check.
Of 102 350 participants included in the individual 
participant data meta-analysis, 20 015 type 2 diabetes 
cases were documented after a median follow-up of 12 
years (interquartile range 9.4-14.2 years). Table 2 and 
supplementary table 7 show the data on participant’s 
dietary intake, genetic risk profile, and covariates. 
Type 2 diabetes genetic risk score mean was 70 (SD 
5.6) units. Baseline mean intakes of total and subtypes 
of fat in percentage of energy were 32.8% (5.9) for total 
fat, 5.8% (1.6) for polyunsaturated fat, 11.9% (2.6) for 
monounsaturated fat, and 12% (2.8) for saturated fat. 
Mean intakes of total omega 3 polyunsaturated fat, 
omega 6 polyunsaturated fat, and trans fat were 1.5 
g/d (0.6), 11.3 g/d (5.7), and 2.0 g/d (1.1), respectively.
Associations of genetic risk and quality of dietary fat 
with incidence of type 2 diabetes
Figure 1 shows that the hazard ratio of type 2 diabetes 
was 1.64 (95% confidence interval 1.54 to 1.75, 
P<0.001, I2=7.1%, τ2=0.003) per increment of 10 risk 
alleles in polygenic risk score after adjusting cohort 
estimates for demographics, lifestyle, and clinical 
characteristics. In meta-analyses for the association 
between the quality of dietary fat and the risk of type 
2 diabetes, the increase of polyunsaturated fat or total 
omega 6 polyunsaturated fat in place of carbohydrate 
(refined starch and sugars) was associated with a lower 
risk of type 2 diabetes, with adjusted hazard ratios of 
0.90 (0.82 to 0.98, P=0.02, I2=18.0%, τ2=0.006; per 
5% of energy; fig 2) and 0.99 (0.97 to 1.00, P=0.05, 
I2=58.8%, τ2=0.001; per increment of 1 g/d; fig 3), 
respectively. The increase of monounsaturated fat in 
place of carbohydrate was associated with a higher risk 
of type 2 diabetes (hazard ratio 1.10, 95% confidence 
interval 1.01 to 1.19, P=0.04, I2=25.9%, τ2=0.006; 
per increment of 5% of energy; fig 4). Isocaloric 
replacement of carbohydrate with total fat, saturated 
fat, total omega 3 polyunsaturated fat, and trans fat 
yielded non-significant associations with adjusted 
hazard ratios of 0.98 (95% confidence interval 0.94 
to 1.02, P=0.26, I2=61.0%, τ2=0.003; per increment 
of 5% of energy; fig 5), 0.95 (0.90 to 1.00, P=0.07, 
I2=0.0%, τ2=0.0; per increment of 5% of energy; fig 
6), 0.95 (0.89 to 1.02, P=0.17, I2=30.9%, τ2=0.005; 
per increment of 1 g/d; fig 7), and 0.98 (0.94 to 1.01, 
P=0.21, I2=2.4%, τ2=0.001; per increment of 1 g/d; fig 
8), respectively.
The association of total omega 6 polyunsaturated 
fat with the risk of type 2 diabetes showed moderate 
Table 2 | Baseline characteristics of patients included in studies that contributed to the meta-analysis of individual participant data on the quality of 
dietary fat and genetic risk of type 2 diabetes. Values are means (SD)
Cohort Age (years) PRS (units) Total fat (%) PUFA (%) MUFA (%) SFA (%) Omega 3 PUFA (g/d) Omega 6 PUFA (g/d) Total trans fat (g/d)
ARIC 53.9 (5.6) 70.1 (5.6) 33.2 (6.7) 5.1 (1.5) 12.7 (2.9) 12.2 (3) 0.8 (0.4) 8.9 (5.3) 3.0 (1.8)
BHS 33.1 (4.9) 67.1 (5.4) 33.8 (4.9) 6.9 (1.4) 12.8 (1.9) 11.2 (2.1) NA NA NA
CHS 72.3 (5.3) 66.5 (5.4) 32.2 (6) 7.5 (2.2) 11.6 (2.4) 10.3 (2.2) 2.2 (1.1) 14.8 (6.7) 3.8 (2.1)
DCH* 56.3 (4.4) 70.1 (5.6) 32.4 (5.3) 5.4 (1.4) 11.8 (2.1) 12.4 (2.7) 2.7 (1.1) 11.5 (5.8) NA
EPIC-InterAct* 53.8 (8.7) 71.2 (5.7) 34.8 (5.7) 5.8 (1.8) 13.6 (3.3) 13.3 (3.4) NA NA NA
FHS 50.8 (13.4) 68.6 (5.4) 31.3 (5.6) 6.0 (1.4) 11.6 (2.4) 10.8 (2.5) 1.5 (0.6) 11.8 (6.7) 2.5 (1.1)
FINRISK 48.4 (13.5) 70.6 (5.5) 31.2 (6.5) 5.8 (1.6) 11.5 (2.7) 10.9 (2.9) 1.3 (0.8) 11.3 (5.6) 2.6 (1.3)
Health 2000 51.6 (11.1) 68.9 (5.5) 36.9 (5.1) 5.5 (1.2) 11.9 (1.9) 14.1 (2.6) 2.8 (1.3) 12.5 (5.8) 1.1 (0.5)
HPFS 54.2 (8.7) 68.9 (5.6) 32.4 (6.2) 5.9 (1.6) 12.4 (2.7) 11.2 (2.7) 1.4 (0.6) 11.9 (5.4) 2.9 (1.6)
Inter99 46.0 (7.8) 70.2 (5.6) 32.6 (7) 5.5 (1.5) 11.1 (2.8) 12.7 (3.5) 0.9 (0.5) 11.4 (6.0) 2.5 (1.2)
MDC-CC 57.3 (6.0) 69.7 (5.4) 36.8 (6.1) 5.9 (1.5) 12.8 (2.2) 15.7 (3.8) 2.4 (0.9) 12.5 (6.3) N/A
MESA 60.5 (9.4) 70.7 (5.6) 31.3 (6.9) 6.1 (1.8) 12.0 (2.8) 10.5 (3.2) 1.2 (0.6) 10.7 (5.9) 3.2 (2.2)
NHS 51.7 (6.7) 68.3 (5.8) 34.8 (5.8) 6.7 (1.8) 12.7 (2.4) 12.5 (2.6) 1.5 (0.6) 10.8 (4.6) 3.8 (1.7)
RS-I 65.3 (6.8) 69.6 (5.6) 36 (6.2) 6.8 (2.7) 12.3 (2.7) 14.2 (3.1) 1.1 (0.5) 12.5 (6.1) 2.1 (0.9)
WGHS 54.6 (7.1) 70.3 (5.5) 30 (6.1) 5.8 (1.5) 11.2 (2.6) 10.2 (2.5) 1.4 (0.6) 10.9 (5.8) 2.3 (1.3)
PRS=polygenic risk score; PUFA=polyunsaturated fat; MUFA=monounsaturated fat; SFA=saturated fat; NA=not available.
*Prospective nested case control.
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Fig 1 | Combined risk of type 2 diabetes per increment of 10 risk alleles in the polygenic 
risk score
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heterogeneity, however, subsequent sensitivity analyses 
testing for single cohort-driven effects did not reveal 
evidence of cohort dominant bias (supplementary fig 
2). We found visual and statistical suggestive evidence 
of small study effects in the contour-enhanced funnel 
plots for the individual participant data meta-analysis 
of the overall association of polyunsaturated fat with 
the risk of type 2 diabetes (Debray’s test P=0.05), 
but not for the omega 6 polyunsaturated fat and 
monounsaturated fat association (Debray’s test 
P=0.70 and P=0.64, respectively, supplementary fig 
3). Evidence of small study effects was likely owing 
to reporting bias given that presumed missing studies 
were mainly allocated in areas of non-significance.40 
We did not detect evidence of ascertainment bias in our 
meta-analytic estimates (supplementary fig 4).
Sensitivity analyses for the association between 
the quality of dietary fat and the risk of type 2 
diabetes in cohorts classified as a low risk of bias 
(n=12) showed consistent findings with the primary 
analysis except for the association between omega 
6 polyunsaturated fat and the risk of type 2 diabetes 
(hazard ratio 0.98, 95% confidence interval 0.97 to 
1.00, P=0.07, I2=65.5%, τ2 <0.001; per increment of 1 
g/d; supplementary fig 5). Further analyses including 
only cohorts with repeated measurements of diet (n=8) 
showed similar findings, except for the association of 
monounsaturated fat and omega 6 polyunsaturated 
fat, with adjusted hazard ratios of 1.10 (95% 
confidence interval 0.97 to 1.25, P=0.12, I2=0.0%, 
τ2=0.0; per increment of 5% of energy) and 0.99 (0.98 
to 1.01, P=0.42, I2=48.2%, τ2 <0.001; per increment 
of 1 g/d), respectively (supplementary fig 6). Isocaloric 
replacement of saturated fat with polyunsaturated fat 
was associated with a lower risk of type 2 diabetes, 
with an adjusted hazard ratio of 0.91 (0.85 to 0.98, 
P=0.02, I2=47.2%, τ2=0.02; per increment of 5% of 
energy; supplementary fig 7).
Interaction between polygenic risk score and 
quality of dietary fat on the risk of type 2 diabetes
Next, we evaluated whether the presence of known 
type 2 diabetes risk-increasing alleles modified the 
association between the quality of dietary fat and 
the risk of type 2 diabetes. In meta-analyses of the 
interaction estimates between polygenic risk score and 
dietary fat subtypes on the risk of type 2 diabetes, we 
did not find evidence of significant interactions (P>0.05 
for interaction; table 3, supplementary fig 8). Results 
were similar when the analysis was restricted to studies 
classified as a low risk of bias (supplementary table 8) 
or when only cohorts with repeated measurements of 
diet were included (supplementary table 9). Similarly, 
in the multivariate meta-analysis, we observed that 
the signal was mainly driven by the main genetic 
effects, with a marginal effect of the interaction term 
(supplementary table 10). In additional analysis to 
investigate whether total or subtypes of fat mediate the 
association between genetic risk and incidence of type 
2 diabetes, we observed that any mediation effect was 
likely to be minimal (supplementary table 11).
Discussion
In the present individual participant data meta-
analysis including 102 350 participants of European 
descent and free of diabetes at baseline from 15 
prospective cohort studies or multicohort consortia, 
we have generated data on the potential interplay 
between genetic and dietary factors on the risk of 
type 2 diabetes. Our results suggest that a polygenic 
risk score computed from known type 2 diabetes risk-
increasing alleles as well as dietary unsaturated fats 
were both associated with the risk of type 2 diabetes, 
with no evidence of meaningful interactions between 
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Fig 2 | Risk of type 2 diabetes associated with isocaloric replacement (5% energy) of 
carbohydrate with polyunsaturated fat
RS-I
Health2000
MDC-CC
NHS
HPFS
ARIC
Inter99
FINRISK
CHS
DCH
MESA
WGHS
FHS
Random effects meta-analysis:
  τ2=0.001; P=0.046; I2=58.8% 0.1 1 10
Cohort Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
324
138
440
1453
939
442
279
172
258
3987
136
1855
289
Cases
2185
1808
3305
7379
4648
6248
5328
3650
255
4801
1399
2025
6421
Controls
0.94 (0.92 to 0.97)
0.95 (0.86 to 1.04)
0.97 (0.94 to 1.00)
0.97 (0.95 to 1.00)
0.97 (0.94 to 1.01)
0.99 (0.95 to 1.03)
0.99 (0.95 to 1.02)
0.99 (0.89 to 1.10)
0.99 (0.96 to 1.03)
0.99 (0.97 to 1.02)
1.00 (0.93 to 1.07)
1.00 (0.98 to 1.02)
1.04 (1.01 to 1.07)
0.99 (0.97 to 1.00)
Fig 3 | Risk of type 2 diabetes associated with isocaloric replacement (1 g/d) of 
carbohydrate with total omega 6 polyunsaturated fat
 o
n
 31 July 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l4292 on 25 July 2019. Downloaded from 
RESEARCH
the bmj | BMJ 2019;366:l4292 | doi: 10.1136/bmj.l4292 7
genetic risk profile and the quality of dietary fat on the 
incidence of type 2 diabetes.
Results in relation to other studies
Currently, major worldwide organizations recommend 
dietary patterns rich in unsaturated fatty acids (both 
monounsaturated fat and polyunsaturated fat) and 
limit the intake of saturated fat and sugars to reduce 
the risk of type 2 diabetes.12 13 Our findings suggest 
that, regardless of genetic risk, consuming more 
polyunsaturated fat in place of refined starch and 
sugars is associated with a lower risk of type 2 diabetes, 
whereas consuming more monounsaturated fat in 
place of carbohydrate is associated with a higher risk 
of type 2 diabetes. These observations are in agreement 
with evidence on intermediate glycemic phenotypes, 
suggesting that only energy intake substitution with 
polyunsaturated fat, but not monounsaturated fat, was 
associated with favorable glycemic levels.16 Our results 
expand these observations to the risk of type 2 diabetes 
and support public health efforts that emphasize the 
consumption of foods rich in polyunsaturated fat.
The positive association between monounsaturated 
fat and the risk of type 2 diabetes is likely to reflect the 
fact that in populations from North America and non-
Mediterranean European countries, which constitute 
the present analysis, animal products are the main 
sources of monounsaturated fat. Therefore, the 
expected benefits of monounsaturated fat on the risk of 
type 2 diabetes might be attenuated depending on the 
food matrix in which they are present,41 42 as recently 
documented for the association between different 
types of monounsaturated fat and coronary artery 
disease risk.25 Furthermore, the lack of association 
when replacing carbohydrate with saturated fat on the 
incidence of type 2 diabetes is consistent with previous 
studies for both incident type 2 diabetes and coronary 
artery disease.15 30 43 The present study, including the 
largest series to date of incident type 2 diabetes cases, 
extended follow-up, and detailed quality of dietary fat 
information, provides further evidence for the primary 
prevention of type 2 diabetes.
The results of the present analysis are in agreement 
with recent evidence that showed no appreciable 
interactions between dietary components and isolated 
type 2 diabetes risk-increasing alleles.44 In addition, 
the Diabetes Prevention Program showed that an 
intensive lifestyle modification is effective for the 
prevention of type 2 diabetes regardless of genetic 
risk.45 Our findings also concur with recent evidence in 
coronary artery disease, suggesting that both genetics 
and lifestyle factors are independently associated with 
the risk of coronary artery disease without evidence 
of interactions.46 In contrast, increasing evidence has 
shown that certain dietary or lifestyle factors such as 
unhealthy dietary patterns, sugar sweetened drinks, 
fried foods, and physical inactivity might interact 
with genetic susceptibility to elevated BMI on the 
risk of developing obesity.20 47-49 However, in lifestyle 
intervention trials for obesity little or no evidence 
of such interactions has emerged.50 51 Such findings 
support the notion that if interactions between genetic 
risk and dietary or lifestyle factors exist, their effects 
are likely to be small or undetected by conventional 
approaches.52 Taken together, these findings support 
lifestyle or dietary interventions for the prevention of 
type 2 diabetes to be deployed across all gradients of 
genetic risk in the population, as genetic burden does 
not seem to impede their effectiveness.
Factors that may have limited the ability to detect 
interactions include the use of a polygenic risk score 
for overall known type 2 diabetes genetic risk. In our 
study, the polygenic risk score is enriched for regulatory 
variants in transcription factor binding sites and 
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Fig 4 | Risk of type 2 diabetes associated with isocaloric replacement (5% energy) of 
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enhancers active in pancreatic islets or adipose tissue, 
therefore reflecting multiple biological pathways.4 
Thus, the score might not be able to uncover potential 
interactions that are driven by specific modulations 
of biological pathways or mechanisms. For example, 
genetic variants related to fat metabolism, such as 
PPARG or FADS, could be more biologically relevant 
for interaction analyses. However, further restraining 
the number of genetic variants will explain a smaller 
proportion of the phenotype, therefore limiting the 
clinical value of potential interactions. Another 
important factor for the lack of interactions is because 
dietary sources of fat involve a heterogeneous blend 
of nutrients and food matrices.53 Thus, the potential 
interaction between subtypes of fat and the genetic 
risk might be attenuated, depending on the food 
matrix in which subtypes of fat are present. Moreover, 
the design and implementation of new studies, such 
as genotype-based recall clinical trials intended for 
the investigation of genetic and lifestyle interactions, 
with more accurate objective measurement of diet are 
required to better understand the interplay between 
genetic and lifestyle factors on the risk of type 2 
diabetes.54
Strengths and limitations
The strengths of this study include the larger number 
of incident type 2 diabetes cases, the harmonized 
covariate definitions and analysis plan among 
participating cohorts, the well validated measures of 
dietary factors and disease ascertainment, and the 
consistency of our findings in sensitivity analyses 
including only cohorts at low risk of bias or cohorts 
with repeated measurements of diet. This is the first 
large long term individual participant data meta-
analysis to investigate whether the quality of dietary 
fat interacts with type 2 diabetes genetic burden on the 
development of type 2 diabetes.
Our study has several potential limitations. First, the 
observational nature of the study design does not allow 
us to infer causality regarding the effect of changes in 
fat intake on the risk of type 2 diabetes. 
Second, although every effort was made to maximize 
the validity of the study, minimize bias, and incorporate 
heterogeneity and uncertainty, the estimated hazard 
ratios of dietary components could be affected by 
measurement error and residual confounding. A 
possible reason for the lack of interaction between the 
polygenic risk score and quality of dietary fat on the 
risk of type 2 diabetes could be imprecision in dietary 
intake measurement. We used cumulative averages 
to yield more precise dietary intake estimates than 
baseline intakes alone,21 but the use of more objective 
measurements of dietary intake such as the use of 
smartphone applications, wearable technology, or 
dietary intake biomarkers, is necessary to accurately 
ascertain dietary intake and reduce self reported 
errors.55
Third, we designed the study to model isocaloric 
replacement of carbohydrate with total or subtypes of 
fat, and thus the study of other nutrients such as the 
amount and subtypes of protein and carbohydrates or 
the replacement of fat with other nutrients might yield 
different findings. 
Fourth, expanding our genetic score to include 
recently discovered low frequency variants in 
relevant type 2 diabetes loci such as PPARG, 
SLC30A8, MTNR1B, G6PC2, or CCND2, or those yet 
undiscovered, could prove useful in subsequent 
analyses. However, previous studies have shown that 
the inclusion of newly discovered type 2 diabetes 
risk-increasing alleles minimally increased type 2 
diabetes heritability estimates.5 In addition, the use of 
weights from case control cross-sectional studies could 
have diminished our chances to detect interactions, 
if genetic effect sizes differed markedly from those 
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Fig 6 | Risk of type 2 diabetes associated with isocaloric replacement (5% energy) of 
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Fig 7 | Risk of type 2 diabetes associated with isocaloric replacement (1 g/d) of 
carbohydrate with total omega 3 polyunsaturated fat
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ascertained in longitudinal studies. However, 
weighted and unweighted polygenic risk scores tend 
to have a comparable performance for complex traits 
prediction,56 57 and the capability of a polygenic risk 
score based on case control weights to predict incident 
type 2 diabetes is consistent.6 7
Fifth, when multiple testing was taken into account 
using Bonferroni’s adjustment, only the polygenic risk 
score association retained significance. 
Finally, the inclusion of only patients of European 
descent based on sample availability might preclude 
the generalizability of our findings to other populations. 
However, our findings supporting the quality of dietary 
fat recommendation for the prevention of type 2 
diabetes to be deployed across all gradients of genetic 
risk in the population could be applicable to other non-
European populations, though further targeted studies 
are required.
Conclusion and policy implications
After evaluating the type 2 diabetes genetic risk profiles 
and the quality of dietary fat among 102 350 patients 
without diabetes at baseline from 15 prospective 
cohort studies, our individual participant data meta-
analysis provides evidence that genetic risk and quality 
of dietary fat are each associated with the incidence 
of type 2 diabetes. Findings from this study serve to 
provide useful clinical answers as we prepare for the 
eventual translation of genetic profiles into clinical 
and public health practice. Our findings support 
dietary or lifestyle interventions for the prevention of 
type 2 diabetes to be deployed across all gradients of 
genetic risk in the population, as genetic burden does 
not seem to impede their effectiveness.
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Table 3 | Interaction between total and subtypes of fat intake and polygenic risk score on the risk of type 2 diabetes
Dietary factor β interaction (SE) P value* Direction of interaction in included studies† τ2‡ Sample size
Total fat, % energy 0.019 (0.015) 0.20 +−+++−++–+– 0 102 350
PUFA, % energy 0.049 (0.061) 0.43 –++++++++−+–+ 0.003 102 350
MUFA, % energy 0.040 (0.032) 0.22 +−+++−−++−+− 0 102 350
SFA, % energy −0.017 (0.031) 0.58 +−+−−+−+− 0 102 350
omega 3 PUFA, g/d 0.025 (0.030) 0.40 −?+−?−+++−+++ 0.002 80 704
omega 6 PUFA, g/d 0.007 (0.005) 0.13 −?++?−+++−+−+ 0 80 704
Total trans fat, g/d 0.009 (0.017) 0.56 −?−??−+−?−+++ 0 68 171
*For interaction.
†For each dietary factor the combined interaction P value, heterogeneity and sample size are shown. Direction of interaction represents the sign of the β 
in each cohort (Cohorts presented in alphabetical order: ARIC, BHS, CHS, DCH, EPIC-InterAct, FHS, FINRISK, Health 2000, HPFS, Inter99, MDC-CC, MESA, 
NHS, RS-1, WGHS).
‡Between study variance (τ2) was used to assess heterogeneity.
PUFA=polyunsaturated fat; MUFA=monounsaturated fat; SE=standard error; SFA=saturated fat; ?=not available.
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